Roche to Acquire Spark Therapeutics
February 25 2019 - 1:44AM
Dow Jones News
By Anthony Shevlin
Roche Holding AG (ROG.EB) said Monday that it entered a
definitive merger agreement to acquire Philadelphia-based Spark
Therapeutics Inc. (ONCE).
The Swiss pharmaceutical company said it would acquire Spark for
$114.50 per share and that the deal is expected to close in the
second quarter.
Under the terms of the deal, Roche will file a tender offer to
acquire all outstanding shares of Spark common stock, and Spark
will file a recommendation statement containing the unanimous
recommendation of the Spark board that its shareholders tender
their shares to Roche.
Spark Therapeutics specializes in discovering, developing and
delivering gene therapies. Its lead clinical asset is SPK-8011, a
novel gene therapy for the treatment of hemophilia A, which is
expected to start Phase 3 trials in 2019.
Roche Chief Executive Severin Schwan said the company planned to
continue investing in Spark's portfolio.
Roche said Spark will continue to operate as an independent
company within the Roche group.
Write to Anthony Shevlin at anthony.shevlin@dowjones.com
(END) Dow Jones Newswires
February 25, 2019 01:29 ET (06:29 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2023 to Apr 2024